Funding for this research was provided by:
U.S. Department of Veterans Affairs (N/A)
Duke Cancer Institute (N/A)
U.S. Department of Veterans Affairs Health Services Research and Development (CDA 14-158)
Received: 22 May 2019
Accepted: 24 September 2019
First Online: 12 November 2019
Ethics approval and consent to participate
: The Durham Veterans Affairs (VA) Medical Center Institutional Review Board approved the Cooperative Studies Program (CSP) #380 study and this secondary analysis under CSP #380 (MIRB #0024): Prospective Evaluation of Risk Factors for Large (1 ≥ cm) Colonic Adenomas in Asymptomatic Subjects. Individual written informed consent was previously obtained during initial recruitment for the CSP #380 (MIRB #0024) protocol.
: Not applicable.
: Terry Hyslop reports fees for serving as an advisory board member on a lung registry trial funded by Astra Zeneca. David Lieberman reports fees for serving as an advisory board member of Motus GI. All other co-authors report no competing interests.